Pre-pandemic pediatric studies looking at accuracy of CGMs in critically ill pediatric patients were conducted before 2015, at a time when CGM was not factory-calibrated and MARD in the outpatient setting was >10%.74–76 They were limited by the small sample, and as expected MARD values were high, indicating that accuracy was not good enough to use CGM values for insulin dosing or treating hypoglycemia without confirmatory capillary glucose testing. This evidence concerns the gene INS and Hypoglycemia.